Technical Analysis for KZIA - Kazia Therapeutics Limited - American Depositary Shares
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Flat |
| See historical KZIA trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 180 Bearish Setup | Bearish Swing Setup | 4.34% | |
| Doji - Bullish? | Reversal | 4.34% | |
| Gapped Down | Weakness | 4.34% | |
| Narrow Range Bar | Range Contraction | -2.59% | |
| Gapped Up | Strength | -2.59% | |
| Narrow Range Bar | Range Contraction | -2.05% | |
| Gapped Down | Weakness | -2.05% | |
| Narrow Range Bar | Range Contraction | -3.30% | |
| NR7 | Range Contraction | -3.30% | |
| NR7-2 | Range Contraction | -3.30% |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 01/23/2019
- Sector: Healthcare
- Industry: Biotechnology
Kazia Therapeutics Limited, formerly Novogen Limited, is an oncology biotechnology company, which is focused on developing cancer treatments. The Company is primarily engaged in pharmaceutical research and development. It has two drug technology platforms (the Superbenzopyran (SBP) technology and Anti-tropomyosin (ATM)) yielding various drug candidates across a range of oncology indications. The Company's product candidates include Cantrixil (TRX-E-002-1), Anisina (ATM-3507) and Trilexium (TRX-E-009-1). The Company's target indication for Cantrixil is ovarian cancer, and Diffuse Intrinsic Pontine Glioma (DIPG) for Trilexium. The initial target pediatric indication for Anisina is neuroblastoma. Cantrixil is the lead development candidate arising from its SBP technology. Anisina is an approach to chemotherapy that targets the cancer cells' actin cytoskeleton. Trilexium (TRX-E-009-1) is its second lead SBP drug candidate.
Biotechnology Cancer ATM Organ Systems Chemotherapy Ovarian Cancer Neuroblastoma Glioma Pharmaceutical Research Diffuse Intrinsic Pontine Glioma
Biotechnology Cancer ATM Organ Systems Chemotherapy Ovarian Cancer Neuroblastoma Glioma Pharmaceutical Research Diffuse Intrinsic Pontine Glioma
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more KZIA news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 5.648 |
| 52 Week Low | 2.04 |
| Average Volume | 4,005 |
| 200-Day Moving Average | 3.1589 |
| 50-Day Moving Average | 3.4055 |
| 20-Day Moving Average | 3.1803 |
| 10-Day Moving Average | 3.0438 |
| Average True Range | 0.1828 |
| ADX | 17.06 |
| +DI | 19.8787 |
| -DI | 28.4608 |
| Chandelier Exit (Long, 3 ATRs ) | 3.1916 |
| Chandelier Exit (Short, 3 ATRs ) | 3.4184 |
| Upper Bollinger Band | 3.5473 |
| Lower Bollinger Band | 2.8133 |
| Percent B (%b) | 0.3 |
| BandWidth | 23.079584 |
| MACD Line | -0.1045 |
| MACD Signal Line | -0.0978 |
| MACD Histogram | -0.0067 |
| Fundamentals | Value |
|---|---|
| Market Cap | 14.67 Million |
| Num Shares | 4.83 Million |
| EPS | -1.80 |
| Price-to-Earnings (P/E) Ratio | -1.69 |
| Price-to-Sales | 2.05 |
| Price-to-Book | 0.71 |
| PEG Ratio | 0.00 |
| Dividend | 0.00 |
| Dividend Yield | 0.00% |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 3.28 | ||||
| Resistance 3 (R3) | 3.27 | 3.17 | 3.24 | ||
| Resistance 2 (R2) | 3.17 | 3.11 | 3.18 | 3.23 | |
| Resistance 1 (R1) | 3.10 | 3.07 | 3.14 | 3.12 | 3.21 |
| Pivot Point | 3.01 | 3.01 | 3.02 | 3.01 | 3.01 |
| Support 1 (S1) | 2.94 | 2.94 | 2.97 | 2.95 | 2.86 |
| Support 2 (S2) | 2.84 | 2.91 | 2.85 | 2.85 | |
| Support 3 (S3) | 2.78 | 2.84 | 2.83 | ||
| Support 4 (S4) | 2.79 |
